SCHEMBL6508348

SCHEMBL6508348

Cc1ccc2nc(N3CCN(c4ccc(F)cc4)CC3)n3c2c1C(=O)CC3

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
MAPT P10636 5/20 0.39
ALDH1A1 P00352 5/20 0.39
LMNA P02545 2/20 0.39
KDM4E B2RXH2 2/20 0.38
MAPK1 P28482 1/20 0.38
HTT P42858 1/20 0.38
GFER P55789 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
RAB9A P51151 2/20 0.37
NPSR1 Q6W5P4 2/20 0.36
MAOB P27338 1/20 0.36
HPGD P15428 1/20 0.36
TP53 P04637 1/20 0.36
TRPV4 Q9HBA0 1/20 0.36
NPC1 O15118 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6507759 0.86 MAPT (0.41) SMN1; SMN2MAPTALDH1A1LMNAKDM4E
SCHEMBL6506280 0.73 DRD2 (0.41) MEN1KMT2ASMN1; SMN2ALDH1A1RAB9A
SCHEMBL6506044 0.72 HCAR1 (0.32) SMN1; SMN2PARP1
SCHEMBL6630480 0.70 MAPT (0.40) MEN1KMT2ASMN1; SMN2MAPTALDH1A1
Hydrochloric Acid SCHEMBL6505881 0.69 MAPT (0.39) MEN1KMT2ASMN1; SMN2MAPTALDH1A1
SCHEMBL6630043 0.66 PARP1 (0.38) SMN1; SMN2MAPTALDH1A1KDM4EHTT
Ethylene SCHEMBL6508802 0.66 GAA (0.39) MEN1KMT2ASMN1; SMN2MAPTALDH1A1
Hydrochloric Acid SCHEMBL6503053 0.65 PARP1 (0.38) SMN1; SMN2MAPTALDH1A1KDM4EHTT
SCHEMBL6503698 0.65 GFER (0.48) MEN1KMT2AMAPTALDH1A1LMNA
SCHEMBL10373626 0.62 MAPT (0.77) MEN1KMT2ASMN1; SMN2MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1309594-B1 BENZIMIDAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2004-12-15 EP claimed
US-20050032779-A1 Benzimidazole derivatives, preparation and therapeutic use thereof SANOFI-AVENTIS (FR) 2005-02-10 US disclosed
EP-1309594-B1 BENZIMIDAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2004-12-15 EP disclosed
US-6794382-B2 6-OXO-5,6-DIHYDRO-4H-IMIDAZO(4,5,1-IJ)QUINOLINE DERIVATIVES AS INHIBITORS OF ADP-RIBOSYLTRANSFERASE; CARDIOVASCULAR, IMMUNOLOGICAL, RESPIRATORY SYSTEM, AND NEURODEGENERATIVE DISORDER TREATMENT SANOFI-SYNTHELABO (FR) 2004-09-21 US disclosed
US-20030203893-A1 Benzimidazole derivatives, preparation and therapeutic use thereof SANOFI-AVENTIS (FR) 2003-10-30 US disclosed
EP-1309594-A1 BENZIMIDAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2003-05-14 EP disclosed
WO-2002012239-A1 BENZIMIDAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-SYNTHELABO (FR) 2002-02-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050032779-A1 Benzimidazole derivatives, preparation and therapeutic use thereof CBR3, CYP3A7, HDAC7 MEN1 4233/4885KMT2A 3767/4885SMN1; SMN2 3970/4885
US-20030203893-A1 Benzimidazole derivatives, preparation and therapeutic use thereof CBR3, HRH4, CBR1 MEN1 4301/4885KMT2A 4037/4885SMN1; SMN2 3713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.